Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma [Phase 1]
A Phase 1 study evaluating BCMA-directed CAR-T cell therapy for relapsed/refractory multiple myeloma has completed enrollment, as reported b…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) [Phase 2]
This document provides a Phase 2 clinical trial update on Anitocabtagene-autoleucel for relapsed or refractory multiple myeloma (iMMagine-1)…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer [Phase 2]
Phase 2 clinical trial comparing GEO-CM04S1 vaccine to an mRNA SARS-CoV-2 vaccine in patients with hematologic malignancies; the study is cu…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/Phase 2 study evaluating dara-RVd and teclistamab-RVd regimens in adults with multiple myelom…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Experimental, and Clinical Research
A multi-method clinical trial is investigating whether fish oil can alleviate bortezomib-induced peripheral neuropathy in patients with mult…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma [Phase 1]
This is a Phase 1 clinical trial update for Anitocabtagene-autoleucel in relapsed/refractory multiple myeloma; the study sponsored by Kite, …
-
CLINICAL_TRIALS trial_result · 2026-02-10Clinical Trial Update: Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant [Phase 2]
Phase 2 study of Daratumumab (Darzalex) in relapsed multiple myeloma after stem cell transplant was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2026-02-10Clinical Trial Update: Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma [Phase 1]
Phase 1 trial evaluating adding KRT-232 (AMG 232) to standard chemotherapy in relapsed multiple myeloma, with plasmacytoma also listed; the …
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma [Phase 1]
This is a Phase 1 clinical trial evaluating an MMSET inhibitor for relapsed and refractory multiple myeloma. Recruitment is ongoing.
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
A Memorial Sloan Kettering Cancer Center study is testing whether maintenance therapy can be stopped in patients with multiple myeloma who a…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001） [EARLY_Phase 1]
An early-phase study update describing a clinical trial evaluating LVIVO-TaVec400 for relapsed or refractory multiple myeloma.
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Self-administration of Subcutaneous Elranatamab in the Patients' Homes. [Phase 2]
Phase 2 trial update on self-administration of subcutaneous elranatamab at patients' homes for multiple myeloma.
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). [Phase 3]
A multicenter open-label Phase 3 study evaluating adding isatuximab to lenalidomide and dexamethasone, with or without bortezomib, in newly …
-
CLINICAL_TRIALS trial_result · 2026-02-10Clinical Trial Update: A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma [Phase 2]
Phase 2 study evaluating selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma; the tria…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects [Phase 1]
Phase 1 clinical trial to compare pharmacokinetics, safety, and immunogenicity of QL2109 with daratumumab in male subjects with multiple mye…
-
CLINICAL_TRIALS trial_result · 2026-02-10Clinical Trial Update: Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma [Phase 2]
A Phase 2 clinical trial update for Arlocabtagene autoleucel (BMS-986393), a GPRC5D-directed CAR T cell therapy, evaluating its use in adult…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial [Phase 4]
Phase 4 clinical trial update evaluating two premedication regimens (methylprednisolone vs dexamethasone-based) to prevent systemic and inje…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]
An early-phase (Phase 1) trial update for SL4903 CAR-T therapy targeting relapsed/refractory multiple myeloma; the study is not yet recruiti…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 1]
Phase 1 clinical trial evaluating CC-95266 in relapsed and/or refractory multiple myeloma has completed.
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
Clinical trial update for cevostamab in relapsed/refractory multiple myeloma, a Phase 1/2 study in patients with prior BCMA exposure, curren…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) [Phase 1, Phase 2]
A Phase 1/2 safety, PK and efficacy study of CC-92480 as monotherapy and in combination with dexamethasone in relapsed and refractory multip…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma [Phase 1]
This clinical trial update describes a Phase 1 study evaluating Teclistamab in combination with Mezigdomide for multiple myeloma. The trial …
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]
Clinical trial update for a Phase 2 study evaluating dasatinib and quercetin in combination with CAR-T therapy for relapsed or refractory mu…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Prehab Prior to Stem Cell Transplantation in Multiple Myeloma [NA]
Clinical trial update from the University of Alberta evaluating prehabilitation before stem cell transplantation in people with multiple mye…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/Phase 2 study of TNB-383B for relapsed or refractory multiple myeloma, sponsored by AbbVie, w…